Seeking Alpha

Gilead (GILD) plans to move forward with the sale of generic versions of four HIV treatments in...

Gilead (GILD) plans to move forward with the sale of generic versions of four HIV treatments in developing countries under the terms of an agreement with a UN-backed patent foundation. New studies show the firm's Truvada HIV pill can prevent the virus transmission, after an early study said the opposite.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|